EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development

Lin Tang, Sheng Pan, Xuyong Wei, Xiao Xu, Qiang Wei

Molecular Therapy · 2023-11 · 31 (11) · 3146-3162

DOI: 10.1016/j.ymthe.2023.09.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2023-11. Verfasst von Lin Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, …. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 204-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic heterogeneity and loss, limited potency and persistence, poor infiltration capacity, and a suppressive tumor microenvironment. To overcome these obstacles, recent studies have reported a new generation of CAR-T cells expressing cytokines called armored CAR-T, TRUCK-T, or the fourth-generation CAR-T. Here we summarize the strategies of arming CAR-T cells with natural or synthetic cytokine signals to enhance their anti-tumor capacity. Moreover, we summarize the advances in CAR-T cells expressing non-cytokine proteins, such as membrane receptors, antibodies, enzymes, co-stimulatory molecules, and transcriptional factors. Furthermore, we discuss several prospective strategies for armored CAR-T therapy development. Altogether, these ideas may provide new insights for the innovations of the next-generation CAR-T therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansCytokinesProspective StudiesImmunotherapy, AdoptiveTumor MicroenvironmentT-Lymphocytes

Stichwörter der Autor:innen

CARbiomedical engineeringcancer immunotherapychimeric antigen receptorcytokinessynthetic biology

Substanzen

Receptors, Chimeric AntigenCytokines

Autor:innen und Institutionen

  • Zhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzho…
  • Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicin…

Förderung

  • National Key Research and Development Program of China
  • Key Research and Development Program of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Tang, L., Pan, S., Wei, X., Xu, X., & Wei, Q. (2023). Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Molecular Therapy, 31(11), 3146-3162. https://doi.org/10.1016/j.ymthe.2023.09.021

Vancouver

Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Molecular Therapy. 2023;31(11):3146-3162. doi:10.1016/j.ymthe.2023.09.021

BibTeX
@article{Tang2023,
  author = {Tang, Lin and Pan, Sheng and Wei, Xuyong and Xu, Xiao and Wei, Qiang},
  title = {Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {11},
  pages = {3146--3162},
  doi = {10.1016/j.ymthe.2023.09.021}
}
Kostenlos starten →